Makary Resigns as FDA Commissioner Following Policy Disputes - Summary - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Makary Resigns as FDA Commissioner Following Policy Disputes

Transition follows disputes over vaccine policy, food additive regulation, and flavored vaping product authorization

  • By

  • Kathryn Wighton

  • May 12, 2026

  • 2 min

Share

Objective:

To report on the resignation of FDA Commissioner Marty Makary and the circumstances surrounding his tenure.

Key Findings:
  • Makary's resignation was influenced by policy disputes and tensions with lawmakers and pharmaceutical companies.
  • His tenure was marked by significant public health decisions during the COVID-19 pandemic.
  • He faced criticism from various stakeholders, including anti-abortion lawmakers and biopharmaceutical companies.
Interpretation:

Makary's resignation reflects the complexities and challenges of leading the FDA amid political and public health controversies.

Limitations:
  • The article does not provide detailed insights into the specific reasons behind the policy disputes.
  • Limited information on the impact of Makary's policies on public health outcomes.
Conclusion:

Marty Makary's resignation highlights the contentious nature of FDA leadership and the challenges faced in navigating public health policy.

Original Source(s)

Makary Resigns as FDA Commissioner Following Policy Disputes

  • by Kathryn Wighton

  • May 12, 2026

Related Content

Top 10 CDC Updates Physicians Should Know

Recent CDC advisories, testing updates, and immunization recommendations highlight developments in infectious diseases, immunization, and diagnostic testing relevant to physicians across multiple specialties.

Can Patients Switch to Biosimilar Aflibercept?

A 20-week INSIGHT extension suggests that switching from reference aflibercept to MYL-1701P maintained comparable safety, visual, and anatomic outcomes in patients with diabetic macular edema.

FDA Approves First Oral PCSK9 Inhibitor

Merck reported placebo-adjusted LDL-C reductions of 56% and 59% at week 24 in two phase 3 CORALreef trials supporting the approval.